Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC).
Phase of Trial: Phase II
Latest Information Update: 18 Aug 2011
At a glance
- Drugs Mitoxantrone; Prednisone; Sorafenib
- Indications Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 03 May 2010 Planned end date changed from Jul 2008 to Jan 2009 as reported by ClinicalTrials.gov.
- 03 May 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.